| 0.6537 0.004 (0.68%) | 07-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.84  |
1-year : | 0.95 |
| Resists | First : | 0.72 |
Second : | 0.81 |
| Pivot price | 0.67 |
|||
| Supports | First : | 0.57 | Second : | 0.47 |
| MAs | MA(5) : | 0.63 |
MA(20) : | 0.67 |
| MA(100) : | 0.74 |
MA(250) : | 1.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.9 |
D(3) : | 36 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 4.98 | Low : | 0.56 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SKYE ] has closed below upper band by 38.8%. Bollinger Bands are 29.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.7 |
| Low: | 0.62 - 0.62 | 0.62 - 0.62 |
| Close: | 0.68 - 0.69 | 0.69 - 0.69 |
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Wed, 01 Jul 2026
SKYE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Tue, 23 Jun 2026
Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall - TradingView
Tue, 23 Jun 2026
Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices - Stock Titan
Thu, 18 Jun 2026
Skye Bioscience, Inc. Stock 12‑Month Price Target Cut to $7.33, Implies 937% Upside - TradingView
Fri, 29 May 2026
Skye Bioscience (NASDAQ: SKYE) holders back major share authorization increase - Stock Titan
Wed, 20 May 2026
Skye Bioscience gets approval to open second cohort in study - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 46 (%) |
| Shares Short | 951 (K) |
| Shares Short P.Month | 1,130 (K) |
| EPS | -1.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.7 % |
| Return on Equity (ttm) | -168 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.48 |
| PEG Ratio | 0 |
| Price to Book value | 2.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|